Evolus 10-Q: $41.7M Cash, $120M Undrawn Debt, Accelerated Jeuveau Inventory Build
EOLS sits 91% above its 52-week low of $3.86.
Summary
Evolus' Q3 10-Q confirms $78.0 million revenue and shows $41.7 million of cash against a $37.8 million stockholders' deficit, with liquidity leaning on $120 million of undrawn debt facilities that must be drawn by December 31, 2026. Inventory and payables ballooned from accelerated Jeuveau imports under a deferred payment deal with Daewoong.
Key Events · Earnings and Guidance · EOLS
-
Q3 Revenue $78.0M, Loss Narrows
Total net revenues of $78.0 million rose 13.0% from $69.0 million, with Jeuveau at $69.3 million and Evolysse at $7.9 million. Net loss was $12.5 million versus $15.7 million a year earlier.
-
Cash $41.7M, Deficit $37.8M
Cash and equivalents fell to $41.7 million from $53.8 million at December 31, 2025, and total stockholders' deficit widened to $37.8 million from $23.1 million.
-
Liquidity Rests on Undrawn Tranches
Management cites $100 million of remaining Pharmakon term-loan tranches, available at the company's election no later than December 31, 2026, plus $20 million of revolver availability as the basis for funding operations for at least twelve months.
-
Inventory and Payables Jump on Tariff Hedge
Inventories rose to $82.8 million from $26.9 million and accounts payable to $86.2 million from $23.4 million as Evolus accelerated Jeuveau imports under a deferred payment arrangement with Daewoong; nine-month operating cash use was $15.5 million versus $55.1 million a year earlier.
Analysis · EOLS · Life Sciences
The headline numbers were already out, but the full 10-Q reveals how thin the equity cushion is: stockholders' deficit widened to $37.8 million and cash fell to $41.7 million from $53.8 million at year-end. Management still says liquidity covers at least twelve months, though that rests on $100 million of undrawn Pharmakon tranches that expire December 31, 2026 plus $20 million left on the revolver. Equally important is the working capital swing: inventory jumped to $82.8 million and payables to $86.2 million because Evolus pulled forward Jeuveau imports from Daewoong under a deferred payment arrangement to get ahead of tariffs. That preserved near-term cash but pushes the payments into later periods, so reported operating cash use of $15.5 million understates the real cash trajectory. On the growth side, the company added U.S. rights to IBSA's Profhilo with no upfront payment and expanded Evolysse into Canada, Australia and New Zealand for EUR 1.4 million upfront.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EOLS was trading at $7.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $493.4M. The 52-week trading range was $3.86 to $9.31. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.